Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06986174 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
A Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia, sponsored by Shayna Sarosiek, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06986174: Recruiting Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia, sponsored by Shayna Sarosiek, MD.
NCT06986174 is a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia that is actively recruiting participants, run by Shayna Sarosiek, MD. The registered enrollment target is 30 participants, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06986174, a Phase 2 study of Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia, is actively recruiting participants, sponsored by Shayna Sarosiek, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)
Primary Outcome
ORR was defined as the percentage of participants achieving complete response (CR), very good partial response (VGPR), partial response (PR) and minimal response (MR) on treatment based on IWWM-11 criteria.
Conditions Studied
Interventions
- DRUG Pacritinib
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2032-10-01 |
| Phase | Phase 2 |
What NCT06986174 shows while recruiting
NCT06986174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 107-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (72% lower).
The record links to 4 conditions, with Lymphoplasmacytic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Pacritinib is the first listed.
NCT06986174 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06986174 about?
NCT06986174 is a clinical study titled "A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia". This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)
What is the current status of trial NCT06986174?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-11-21. Estimated completion is 2032-10-01.
What conditions does trial NCT06986174 study?
This clinical trial studies the following conditions: Lymphoplasmacytic Lymphoma, Waldenström Macroglobulinemia, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma.
What interventions are being tested in trial NCT06986174?
The interventions under investigation include: Pacritinib (DRUG).
Who is sponsoring clinical trial NCT06986174?
This trial is sponsored by Shayna Sarosiek, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06986174 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoplasmacytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06986174's enrollment target sits among peer trials
30 14th of 18 higher than 4 of 18 other Lymphoplasmacytic Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoplasmacytic Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI